Cargando…
Computational Cell Cycle Profiling of Cancer Cells for Prioritizing FDA-Approved Drugs with Repurposing Potential
Discovery of first-in-class medicines for treating cancer is limited by concerns with their toxicity and safety profiles, while repurposing known drugs for new anticancer indications has become a viable alternative. Here, we have developed a new approach that utilizes cell cycle arresting patterns a...
Autores principales: | Lo, Yu-Chen, Senese, Silvia, France, Bryan, Gholkar, Ankur A., Damoiseaux, Robert, Torres, Jorge Z. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5595967/ https://www.ncbi.nlm.nih.gov/pubmed/28900159 http://dx.doi.org/10.1038/s41598-017-11508-2 |
Ejemplares similares
-
Geroscience‐guided repurposing of FDA‐approved drugs to target aging: A proposed process and prioritization
por: Kulkarni, Ameya S., et al.
Publicado: (2022) -
Microtubins: a novel class of small synthetic microtubule targeting drugs that inhibit cancer cell proliferation
por: Senese, Silvia, et al.
Publicado: (2017) -
A LCMT1-PME-1 methylation equilibrium controls mitotic spindle size
por: Xia, Xiaoyu, et al.
Publicado: (2015) -
Repurposing FDA-approved drugs for anti-aging therapies
por: Snell, Terry W., et al.
Publicado: (2016) -
Repurposing of FDA-approved drugs against cancer – focus on metastasis
por: Ozsvári, Béla, et al.
Publicado: (2016)